Univest
Univest
  • Markets
  • Alivus Life Sciences Analyst Review 2027: Profit Jumps 51% as Stock Runs Past Broker Target

    • November 18, 2026
    • Posted by: Chaitanya Auti
    • Category: Market
    No Comments
    Alivus Life Sciences Analyst Review 2027: Profit Jumps 51% as Stock Runs Past Broker Target

    Alivus Life Sciences, formerly Glenmark Life Sciences, grew Q2 FY27 profit about 51% to ₹196.7 crore on a 41.8% EBITDA margin, and the stock now trades above ICICI Securities’ ₹1,330 target. We review results, segments, guidance and risks.

    read more